Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.9 USD | +5.21% | +16.20% | +33.91% |
Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Apr. 18 | Verastem Oncology Announces Executive Changes | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 30.71M | Capitalization | 276M |
---|---|---|---|---|---|
Net income 2024 * | -130M | Net income 2025 * | -117M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.98 x |
P/E ratio 2024 * |
-2.57
x | P/E ratio 2025 * |
-3.66
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.43% |
1 day | +5.21% | ||
1 week | +16.20% | ||
Current month | +9.22% | ||
1 month | -3.80% | ||
3 months | -11.02% | ||
6 months | +59.12% | ||
Current year | +33.91% |
Managers | Title | Age | Since |
---|---|---|---|
Dan Paterson
CEO | Chief Executive Officer | 63 | 10-12-31 |
Daniel Calkins
DFI | Director of Finance/CFO | 37 | 18-11-30 |
Jonathan Pachter
CTO | Chief Tech/Sci/R&D Officer | 66 | 11-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Rowinsky
BRD | Director/Board Member | 67 | 17-05-02 |
John Johnson
BRD | Director/Board Member | 66 | 20-04-22 |
Michael Kauffman
CHM | Chairman | 60 | 12-11-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.47% | 4 M€ | -5.15% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 10.9 | +5.21% | 104,270 |
24-05-02 | 10.36 | +3.81% | 78,935 |
24-05-01 | 9.98 | 0.00% | 91,210 |
24-04-30 | 9.98 | +3.63% | 83,804 |
24-04-29 | 9.63 | +2.67% | 39,824 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.91% | 276M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- VSTM Stock